Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
JAMA|September 2, 2015
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical TrialGeorge L Bakris, Rajiv Agarwal, Juliana C Chan, et al.Clinical Journal of the American Society of Nephrology : CJASN|March 17, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup AnalysisPantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, et al.Kidney Medicine|December 4, 2023
Finerenone in Black Patients With Type 2 Diabetes and CKD: A Post hoc Analysis of the Pooled FIDELIO-DKD and FIGARO-DKD TrialsJohn M Flack, Rajiv Agarwal, Stefan D Anker, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 1, 2021
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE resultsRajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, et al.European Heart Journal. Cardiovascular Pharmacotherapy|October 17, 2022
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular diseaseGerasimos Filippatos, Stefan D Anker, Bertram Pitt, et al.Clinical Kidney Journal|March 3, 2023
A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney diseaseRajiv Agarwal, Bertram Pitt, Biff F Palmer, et al.Kidney Medicine|September 25, 2023
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY AnalysisSylvia E Rosas, Luis M Ruilope, Stefan D Anker, et al.European Heart Journal. Cardiovascular Pharmacotherapy|January 13, 2023
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysisGerasimos Filippatos, Stefan D Anker, Phyllis August, et al.Pageof 4